<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3910</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2018</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">18</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1908 - 1908</td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.peripheralBloodInvolvement<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>Peripheral blood involvement, summarized in "B category", refers to the percentage of peripheral blood lymphocytes that are atypical (Sezary) cells and whether they are "Clone negative" or "Clone positive".</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para'>Peripheral blood involvement is a prognostic factor required in AJCC 8th edition, Chapter 81


    <em>Primary Cutaneous Lymphomas</em>, for staging of Mycosis Fungoides and Sezary Syndrome. It was previously collected as Mycosis Fungoides, CS SSF #1.
</div>
<div class='content chap10-para'><strong>Codes</strong></div>
<div class='content chap10-para'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>0</td>
            <td class='code-desc'>Absence of significant blood involvement<br/>
                5% or less of peripheral blood lymphocytes are atypical (Sezary) cells<br/>
                Clone unknown<br/>
                Stated as B0
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>1</td>
            <td class='code-desc'>Absence of significant blood involvement<br/>
                5% or less of peripheral blood lymphocytes are atypical (Sezary) cells<br/>
                Clone negative<br/>
                Stated as B0a
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>2</td>
            <td class='code-desc'>Absence of significant blood involvement:<br/>
                5% or less of peripheral blood lymphocytes are atypical (Sezary) cells<br/>
                Clone positive<br/>
                Stated as B0b
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>3</td>
            <td class='code-desc'>Low blood tumor burden<br/>
                More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2<br/>
                Clone unknown<br/>
                Stated as B1
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>4</td>
            <td class='code-desc'>Low blood tumor burden<br/>
                More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2<br/>
                Clone negative<br/>
                Stated as B1a
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>5</td>
            <td class='code-desc'>Low blood tumor burden<br/>
                More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2<br/>
                Clone positive<br/>
                Stated as B1b
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>6</td>
            <td class='code-desc'>High blood tumor burden<br/>
                Greater than or equal to 1000 Sezary cells per microliter (uL)<br/>
                Clone positive<br/>
                Stated as B2
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>7</td>
            <td class='code-desc'>Test ordered, results not in chart</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>9</td>
            <td class='code-desc'>Not documented in medical record<br/>
                Peripheral Blood Involvement not assessed or unknown if assessed
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'></td>
            <td class='code-desc'></td>
        </tr>
    </table>
</div>
<div class='content chap10-para'>Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.</div>